Zynex Announces Uplisting to the Nasdaq Global Select Market®
Zynex (NASDAQ: ZYXI) announced its uplisting to the Nasdaq Global Select Market, effective July 14, 2021. This achievement highlights Zynex's strong growth and financial performance, meeting stringent financial, liquidity, and governance criteria. CEO Thomas Sandgaard emphasized the importance of this milestone for enhancing shareholder value. The company specializes in non-invasive medical devices for pain management, stroke rehabilitation, and cardiac monitoring. Zynex's proprietary products include electrotherapy devices and blood volume monitors.
- Uplisting to the Nasdaq Global Select Market reflects strong company growth and financial performance.
- Enhanced visibility and credibility in the market may attract more investors.
- Potential risks related to future financial performance due to market uncertainties.
- Dependence on third-party manufacturers could impact product availability.
ENGLEWOOD, Colo., July 13, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that effective as of market open on July 14, 2021, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "ZYXI."
The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
"Meeting the requirements for the Nasdaq Global Select Market® demonstrates our strong growth and financial performance in recent years," said Thomas Sandgaard, CEO of Zynex. "I want to thank our dedicated employee base as we work diligently to execute our growth strategy and improve shareholder value."
About Zynex, Inc.
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-uplisting-to-the-nasdaq-global-select-market-301332499.html
SOURCE Zynex
FAQ
What does Zynex's uplisting to Nasdaq Global Select Market mean for investors?
When did Zynex uplist to the Nasdaq Global Select Market?
What is Zynex's primary area of focus?
How might Zynex's uplisting affect its stock performance?
